Table 4.
Results of genotyping of PALB2 mutation carriers
| Proband no. | Marker position bp |
D16S403 22,977,651 |
D16S481 23,188,290 |
PALB2 23,554,483* |
D16S417 23,717,034 |
|---|---|---|---|---|---|
| 293 | Ov. Ca. | 2, 3 | 1, 2 | c.509-510delGA | 2, 4 |
| 375 | Ov. Ca. | 2, 6 | 1, 2 | c.509-510delGA | 2, 4 |
| ZB649 | Control | 4, 3 | 1, 2 | c.509-510delGA | 3, 4 |
| 802 | Br. Ca. | 1, 6 | 3, 2 | c.509-510delGA | 2, 4 |
| 2076 | Br. Ca. | 4, 5 | 1, 1 | c.509-510delGA | 2, 1 |
| 893 | Br. Ca. | 4, 3 | 1, 2 | c.509-510delGA | 3, 4 |
| 1540 | Br. Ca. | 4, 3 | 1, 1 | c.509-510delGA | 2, 4 |
Alleles for each microsatellite marker were numbered according to the size. Ov. Ca. - ovarian cancer patients; Control - a PALB2 mutation carrier from the control group; Br. Ca. - breast cancer patients
* the position of PALB2 gene on chromosome 16 (NCBI reference sequence: NT_010393.16); the position of the deletion is 23,587,357 bp